Josh Gottheimer Sells Shares of Abbott Laboratories $ABT

Key Points

  • Josh Gottheimer sold Abbott Laboratories ($ABT) stock ($1,001 - $15,000).
  • The trade was disclosed by a member of the House.
  • $ABT last traded around $89.77.
Congressional trading track record

Josh Gottheimer vs. the S&P 500

YTD return -11.1% hypothetical
All-time return +42.7% S&P 500 +78.9%
vs. S&P 500 -36.2% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

Josh Gottheimer, a member of the House, sold $1,001 - $15,000 of Abbott Laboratories ($ABT) stock on 2026-05-27, according to a periodic transaction report filed under the STOCK Act. Disclosures are filed after the trade and reflect a dollar range, not an exact amount.

Abbott Laboratories ($ABT) Stock

Last price$89.77
Market cap$154.45B
P/E ratio24.84
Forward P/E14.63
PEG ratio1.32
Beta0.62
52-week low$81.97
52-week high$139.06
50-day MA$90.93
200-day MA$114.28
Current ratio1.39
Quick ratio0.84
Debt-to-equity0.65

Abbott Laboratories Earnings

EPS (ttm)$3.57
Revenue (ttm)$45.13B
Revenue growth7.8%
Net margin13.9%
Return on equity12.3%
Next earningsApr 16, 2026

Abbott Laboratories Dividend

Annual dividend$2.52
Dividend yield284.00%
Payout ratio67.2%
Ex-dividend dateJul 15, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$116.54
High target$135.00
Low target$92.00
Analysts covering24

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

ExchangeNYSE
SectorHealthcare
IndustryMedical Devices
HeadquartersAbbott Park, IL
CEOMr. Philip P. Boudreau
Employees122,000

See Also

This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.